Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage.

Hostager R, Ragonnet-Cronin M, Murrell B, Hedskog C, Osinusi A, Susser S, Sarrazin C, Svarovskaia E, Wertheim JO.

Virus Evol. 2019 Oct 9;5(2):vez041. doi: 10.1093/ve/vez041. eCollection 2019 Jul.

2.

The 'Disappearing' Liver on CEUS: Nothing to Worry About.

Müller T, Posnien F, Sarrazin C.

Ultrasound Int Open. 2019 Mar;5(2):E78-E79. doi: 10.1055/a-1005-7459. Epub 2019 Sep 26. No abstract available.

3.

Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.

Aregay A, Owusu Sekyere S, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H.

J Hepatol. 2019 Nov;71(5):889-899. doi: 10.1016/j.jhep.2019.06.025. Epub 2019 Jul 8.

PMID:
31295532
4.

Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.

Mücke VT, Thomas D, Mücke MM, Waidmann O, Zeuzem S, Sarrazin C, Pfeilschifter J, Vermehren J, Finkelmeier F, Grammatikos G.

Liver Int. 2019 Jun 17. doi: 10.1111/liv.14178. [Epub ahead of print]

PMID:
31207039
5.

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.

Sarrazin C, Buggisch P, Mauss S, Müller T, Zimmermann T, Klinker H, Pathil-Warth A, Schlag M, Nalpas C, Wegner S, Lonjon-Domanec I, Simon KG.

Z Gastroenterol. 2019 May;57(5):584-592. doi: 10.1055/a-0859-7561. Epub 2019 May 13.

PMID:
31083746
6.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
7.

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.

Jensen SB, Fahnøe U, Pham LV, Serre SBN, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky JM, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM.

Hepatology. 2019 Sep;70(3):771-787. doi: 10.1002/hep.30647. Epub 2019 Jun 5.

8.

Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections.

Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung MC, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F.

Eur J Gastroenterol Hepatol. 2019 Jul;31(7):845-852. doi: 10.1097/MEG.0000000000001351.

PMID:
30789375
9.

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study.

Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J.

Open Forum Infect Dis. 2018 Dec 15;6(1):ofy340. doi: 10.1093/ofid/ofy340. eCollection 2019 Jan.

10.

[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)].

Hüppe D, Serfert Y, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Günther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H.

Z Gastroenterol. 2019 Jan;57(1):27-36. doi: 10.1055/a-0821-7188. Epub 2019 Jan 14. German.

PMID:
30641600
11.

SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations.

Costa R, Todt D, Zapatero-Belinchón F, Schenk C, Anastasiou OE, Walker A, Hertel B, Timmer L, Bojkova D, Ruckert M, Sarrazin C, Timm J, Lohmann V, Manns MP, Steinmann E, von Hahn T, Ciesek S.

J Hepatol. 2019 Apr;70(4):603-614. doi: 10.1016/j.jhep.2018.11.012. Epub 2018 Nov 23.

PMID:
30472319
12.

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.

Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T.

Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029. Epub 2018 Nov 19.

13.

Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection.

Mücke VT, Jakobi K, Knop V, Thomas D, Mücke MM, Peiffer KH, Zeuzem S, Sarrazin C, Pfeilschifter J, Grammatikos G.

PLoS One. 2018 Nov 15;13(11):e0207293. doi: 10.1371/journal.pone.0207293. eCollection 2018.

14.

HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.

van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky JM, Cloherty GA, Duarte-Rojo A, Sarrazin C, Wedemeyer H, Feld JJ.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864. doi: 10.1016/S2468-1253(18)30271-1. Epub 2018 Sep 28.

PMID:
30274834
15.

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bourliere M, Zeuzem S, Flamm SL.

J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.

PMID:
30098373
16.

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C.

Gut. 2019 Jun;68(6):1099-1107. doi: 10.1136/gutjnl-2018-316228. Epub 2018 Aug 1.

PMID:
30068662
17.

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.

Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J.

Liver Int. 2018 Nov;38(11):1906-1910. doi: 10.1111/liv.13932. Epub 2018 Aug 10.

PMID:
30022590
18.

S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“.

Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S.

Z Gastroenterol. 2018 Jul;56(7):e53-e115. doi: 10.1055/a-0598-5242. Epub 2018 Jul 9. German. No abstract available.

PMID:
29986357
Free Article
19.

Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients.

Welker MW, Weiler N, Bechstein WO, Herrmann E, Betz C, Schöffauer M, Zeuzem S, Sarrazin C, Amann K, Jung O.

J Nephrol. 2019 Feb;32(1):129-137. doi: 10.1007/s40620-018-0506-2. Epub 2018 Jun 26.

PMID:
29946864
20.

[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012].

Sarrazin C, Zimmermann T, Berg T, Neumann UP, Schirmacher P, Schmidt H, Spengler U, Timm J, Wedemeyer H, Wirth S, Zeuzem S; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Pathologie e.V. (DGP); Deutsche Leberstiftung; Gesellschaft für Virologie e.V. (GfV); Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE); Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH); Schweizerische Gesellschaft für Gastroenterologie (SGG); Deutsche Transplantationsgesellschaft e.V. (DTG); Deutsche Leberhilfe e.V; Deutsche Gesellschaft für Infektiologie e.V. (DGI); Deutsche Gesellschaft für Suchtmedizin e.V. (DGS); Deutsche AIDS-Gesellschaft e.V. (DAIG); Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ); Robert Koch-Institut.

Z Gastroenterol. 2018 Jul;56(7):756-838. doi: 10.1055/a-0599-1320. Epub 2018 Jun 26. German. No abstract available.

21.

Letter: impact of HBV genotypes and PC/BCP mutations on serum HBsAg levels in Chinese HBeAg negative patients-Authors' reply.

Kuhnhenn L, Jiang B, Kubesch A, Zeuzem S, Sarrazin C, Hildt E, Peffer KH.

Aliment Pharmacol Ther. 2018 Jul;48(2):238-239. doi: 10.1111/apt.14836. No abstract available.

PMID:
29939412
22.

Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy.

Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horváth G, Jancsik V, Lengyel G, Makkai E, Pár A, Péter Z, Pusztay M, Ribiczey P, Rókusz L, Sarrazin C, Schneider F, Susser S, Szalay F, Tornai I, Tusnádi A, Újhelyi E, Werling K, Makara M.

Clin Exp Hepatol. 2018 Jun;4(2):83-90. doi: 10.5114/ceh.2018.75957. Epub 2018 May 25.

23.

Treatment of chronic hepatitis C.

Forns X, Sarrazin C.

J Hepatol. 2018 Aug;69(2):544-546. doi: 10.1016/j.jhep.2018.04.011. Epub 2018 Jun 8. No abstract available.

PMID:
29891100
24.

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O.

Liver Cancer. 2018 May;7(2):190-204. doi: 10.1159/000486812. Epub 2018 Mar 1.

25.

Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs.

Saleh M, Welsch C, Cai C, Döring C, Gouttenoire J, Friedrich J, Haselow K, Sarrazin C, Badenhoop K, Moradpour D, Zeuzem S, Rueschenbaum S, Lange CM.

J Steroid Biochem Mol Biol. 2018 Oct;183:142-151. doi: 10.1016/j.jsbmb.2018.06.008. Epub 2018 Jun 7.

PMID:
29885880
26.

Editorial: HBsAg serum levels in HBeAg-negative chronic HBV infection-is it a matter of genotype? Authors' reply.

Kuhnhenn L, Jiang B, Kubesch A, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH.

Aliment Pharmacol Ther. 2018 Jul;48(1):103-104. doi: 10.1111/apt.14793. No abstract available.

PMID:
29882986
27.

Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.

von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 Jun;47(11):1550-1551. doi: 10.1111/apt.14648. No abstract available.

PMID:
29878436
28.

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.

Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP.

PLoS One. 2018 Jun 6;13(6):e0197544. doi: 10.1371/journal.pone.0197544. eCollection 2018.

29.

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.

Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH.

Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535. doi: 10.1111/apt.14636. Epub 2018 Apr 10.

PMID:
29637585
30.

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.

Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C.

J Infect Chemother. 2018 Jul;24(7):524-530. doi: 10.1016/j.jiac.2018.02.008. Epub 2018 Apr 5.

PMID:
29628383
31.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592. Epub 2018 Mar 14.

32.

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.

Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E.

J Infect Dis. 2018 Jun 5;218(1):114-123. doi: 10.1093/infdis/jiy119.

PMID:
29528436
33.

Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting.

Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S.

United European Gastroenterol J. 2018 Mar;6(2):213-224. doi: 10.1177/2050640617716607. Epub 2017 Jun 17.

34.

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group.

Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.

PMID:
29146520
35.

Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study.

Maasoumy B, Bremer B, Lehmann P, Marins EG, Michel-Treil V, Simon CO, Njoya M, Cornberg M, Paxinos E, Manns MP, Vermehren J, Sarrazin C, Sohn JY, Cho Y, Wedemeyer H.

Therap Adv Gastroenterol. 2017 Aug;10(8):609-618. doi: 10.1177/1756283X17722745. Epub 2017 Aug 7.

36.

Predictive Value of Computed Tomography Scans and Clinical Findings for the Need of Endoscopic Necrosectomy in Walled-off Necrosis From Pancreatitis.

Finkelmeier F, Sturm C, Friedrich-Rust M, Bojunga J, Sarrazin C, Tal A, Hausmann J, Zeuzem S, Zangos S, Albert J, Farnik H.

Pancreas. 2017 Sep;46(8):1039-1045. doi: 10.1097/MPA.0000000000000881.

PMID:
28796138
37.

High prevalence of antibodies to core+1/ARF protein in HCV-infected patients with advanced cirrhosis.

Kassela K, Karakasiliotis I, Charpantidis S, Koskinas J, Mylopoulou T, Mimidis K, Sarrazin C, Grammatikos G, Mavromara P.

J Gen Virol. 2017 Jul;98(7):1713-1719. doi: 10.1099/jgv.0.000851. Epub 2017 Jul 15.

PMID:
28708052
38.

No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort.

Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J.

Aliment Pharmacol Ther. 2017 Aug;46(4):432-439. doi: 10.1111/apt.14177. Epub 2017 Jun 19.

39.

Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C.

J Hepatol. 2017 Oct;67(4):680-686. doi: 10.1016/j.jhep.2017.05.027. Epub 2017 Jun 13.

PMID:
28619439
40.

Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.

Westhaus S, Deest M, Nguyen ATX, Stanke F, Heckl D, Costa R, Schambach A, Manns MP, Berg T, Vondran FWR, Sarrazin C, Ciesek S, von Hahn T.

J Hepatol. 2017 Aug;67(2):237-245. doi: 10.1016/j.jhep.2017.03.020. Epub 2017 Mar 29.

PMID:
28363797
41.

HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.

Rockstroh JK, Feld JJ, Chevaliez S, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, Herman C, Hackett J Jr, Cohen DE, Dawson GJ, Cloherty G, Pawlotsky JM.

J Virol Methods. 2017 Jul;245:14-18. doi: 10.1016/j.jviromet.2017.03.002. Epub 2017 Mar 27.

42.

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H.

J Viral Hepat. 2017 Oct;24(10):840-849. doi: 10.1111/jvh.12708. Epub 2017 May 25.

PMID:
28342229
43.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

44.

Application of Hemoadsorption in a Case of Liver Cirrhosis and Alcohol-Related Steatohepatitis with Preexisting Hepatitis C Infection.

Büttner S, Patyna S, Koch B, Finkelmeier F, Geiger H, Sarrazin C, Farnik H.

Blood Purif. 2017;44(1):30-31. doi: 10.1159/000455064. Epub 2017 Feb 25. No abstract available.

45.

Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients.

Weiler N, Bilge N, Troetschler S, Vermehren J, Schnitzbauer AA, Herrmann E, Sarrazin C, Zeuzem S, Welker MW.

J Clin Pharmacol. 2017 Jul;57(7):837-845. doi: 10.1002/jcph.871. Epub 2017 Jan 30.

PMID:
28134984
46.

Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms.

Vermehren J, Stelzl E, Maasoumy B, Michel-Treil V, Berkowski C, Marins EG, Paxinos EE, Marino E, Wedemeyer H, Sarrazin C, Kessler HH.

J Clin Microbiol. 2017 Apr;55(4):1131-1139. doi: 10.1128/JCM.02193-16. Epub 2017 Jan 25.

47.

Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.

Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP.

J Hepatol. 2017 Apr;66(4):862-863. doi: 10.1016/j.jhep.2017.01.002. Epub 2017 Jan 9. No abstract available.

PMID:
28082147
48.

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.

Cornberg M, Petersen J, Schober A, Mauss S, Böker KH, Link R, Günther R, Serfert Y, Pfeiffer-Vornkahl H, Manns MP, Sarrazin C, Hüppe D, Berg T, Niederau C.

Aliment Pharmacol Ther. 2017 Mar;45(5):688-700. doi: 10.1111/apt.13925. Epub 2017 Jan 12.

49.

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.

Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M.

PLoS One. 2017 Jan 5;12(1):e0168713. doi: 10.1371/journal.pone.0168713. eCollection 2017.

50.

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.

Sarrazin C, Manns M, Calleja JL, Garcia-Samaniego J, Forns X, Kaste R, Bai X, Wu J, Stern JO.

PLoS One. 2016 Dec 28;11(12):e0168544. doi: 10.1371/journal.pone.0168544. eCollection 2016.

Supplemental Content

Loading ...
Support Center